- Home
- GENI vs BEAM Comparison
GENI vs BEAM Comparison
Compare GENI & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GENI | BEAM |
|---|---|---|
| Founded | 2016 | 2017 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Services-Misc. Amusement & Recreation | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 2.7B |
| IPO Year | 2021 | 2019 |
Fundamental Metrics
Financial Performance| Metric | GENI | BEAM |
|---|---|---|
| Price | $5.18 | $25.52 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 16 | 16 |
| Target Price | $13.19 | ★ $49.13 |
| AVG Volume (30 Days) | ★ 5.9M | 1.7M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 82.31 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $24,000.00 |
| Revenue This Year | $29.73 | N/A |
| Revenue Next Year | $28.38 | $35.80 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 33.33 |
| 52 Week Low | $4.96 | $13.53 |
| 52 Week High | $13.73 | $36.44 |
Technical Indicators
Market Signals| Indicator | GENI | BEAM |
|---|---|---|
| Relative Strength Index (RSI) | 29.30 | 42.07 |
| Support Level | N/A | $23.84 |
| Resistance Level | $6.75 | $25.69 |
| Average True Range (ATR) | 0.43 | 1.94 |
| MACD | 0.03 | -0.23 |
| Stochastic Oscillator | 11.46 | 8.70 |
Price Performance
Historical ComparisonAbout GENI Genius Sports Limited
Genius Sports Ltd is a B2B provider of scalable, technology-led products and services to the sports, sports betting, and sports media industries. Its services are organized into three key product areas including Sports Technology and Services; Betting Technology, Content and Services; and Media Technology, Content and Services. All of its products are powered by proprietary technology and robust data infrastructure. It generates maximum revenue from the Betting Technology, Content and Services division. Geographically, the company derives a majority of its revenue from Europe.
About BEAM Beam Therapeutics Inc.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.